[Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children].
OBJECTIVE
To investigate the efficacy and safety of ademetionine for treatment of cholestatic or mixed-type drug-induced liver disease (DILD) in children.


METHODS
The children with DILD were divided into the treated group and control group. Yinzhihuang Granule was orally administered and Compound Glycyrrhizin Injection intravenously given in patients of both groups. Those patients in the treated group were additionally treated with intravenous infusion of 250-1000 mg ademetionine for 28 d. The incidence of pruritus and adverse effects as well as biochemical parameters in all the patients and compared between the 2 groups. For statistical analysis, Chi2 test was used for between-group comparison and t test for processing the data.


RESULTS
1) Before treatment, severe pruritus was found in 17 and 16 children in the treated and control group, respectively. Two weeks after the treatment, the symptom was significantly relieved in 14 and 3 patients in the treated and control group, respectively (Chi2 = 4.52, P < 0.05). 2) As for comparisons between the 2 groups, a P value of 0.0014 for AST level was found 4 weeks, 0.045 and 0.007 for disappearance and recovery rate of jaundice, 0.0014 and 0.0006 for decrease in TBA level and 0.0003 for gammaGT level 2 and 4 weeks after the treatment.


CONCLUSIONS
Intravenous administration of ademetionine is safe in children with DILD and it can effectively alleviate pruritus, promote the recovery of various biochemical parameters and fasten liver functional recovery in these children. Therefore, ademetionine can be widely used for treatment of intrahepatic cholestasis in children.
The Fifth Department of Infectious Diseases, 302 Hospital of PLA, Beijing, China.
Shi-Shu
SS
Zhu
Yi
Y
Dong
Yu
Y
Gan
Hong-Mei
HM
Tang
Zhi-Qiang
ZQ
Xu
Da-Wei
DW
Chen
Wen-Zheng
WZ
Jia
Li-Min
LM
Wang
Hong-Fei
HF
Zhang
D000293:Adolescent; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D012436:S-Adenosylmethionine / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
D012436:S-Adenosylmethionine